Goal Oriented Strategy to Preserve Ejection Fraction Trial

NCT ID: NCT03236818

Last Updated: 2017-08-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2017-09-30

Brief Summary

In this prospective long term feasibility study we examine whether a goal oriented therapeutic strategy that is able to preserve right ventricular function will result in improved clinical outcome in patients with pulmonary arterial hypertension. We hypothesize that right ventricular function can only be preserved when early and aggressive medical combination therapy not only reduces pulmonary vascular resistance but also pulmonary pressures.

Detailed Description

Rationale:

The current strategy in patients with pulmonary arterial hypertension (PAH)is to improve exercise capacity which can be achieved by decreasing pulmonary vascular resistance (PVR) and subsequently increasing cardiac output (CO). Despite this load reduction, a substantial proportion of patients show progressive right ventricular (RV) dysfunction leading to clinical worsening and death. A possible explanation is that current therapies show a relatively modest reduction in PVR, leaving mean pulmonary artery pressure (mPAP) unchanged. As a consequence RV work, defined as the product of CO and mPAP increases, contributing to progressive RV dysfunction.

Hypothesis:

A goal oriented therapeutic strategy that is able to preserve RV function will result in improved clinical outcome. RV function can only be preserved when early and aggressive combination therapy not only reduces PVR but also mPAP.

Study questions:

1. Will a goal oriented strategy to preserve/improve RV function, measured by right ventricular ejection fraction (RVEF) be effective?

2. Does early and aggressive combination therapy result in improved RV function and survival during long term follow-up?

3. Does a strategy to preserve RVEF also translate into improvements of other clinically meaningful parameters?

4. Can RVEF be replaced by more simple measures?

5. Will a goal oriented strategy to improve RVEF also lead to improvement of myocardial performances and coupling of the RV to its load?

Study design and study population:

In this prospective longitudinal feasibility study, thirty newly diagnosed idiopathic or heritable PAH patients with New York Heart Association (NYHA) functional class II or III will be included. Maintenance/improvement of RVEF will be our primary outcome parameter and therefore cardiac magnetic resonance imaging (CMR) will be performed at baseline and at 4, 8 , 12 and 24 months of follow-up. Six-minute walk testing (6MWT), quality of life questionnaires and blood sampling (NT-proBNP) will be performed at similar follow-up intervals. In addition, right heart catheterization (RHC) will be performed at baseline, after 4, 12 and 24 months of follow-up.

NYHA II patients will start with single agent medical treatment whereas patients with NYHA III will start on combination therapy (2 treatments). In case of a stable/improved RVEF during each follow-up measurement (defined as no decrease in RVEF >3% compared to previous measurement), the treatment strategy will remain unchanged. In case of decreased RVEF >3%, additional medical therapy will be added. Our hypothesis will prove to be correct when the additional medical treatment result in improved RVEF during the subsequent follow-up measurement.

Conditions

Pulmonary Arterial Hypertension

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Upfront combination therapy

Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)

Group Type: OTHER

ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)

Intervention Type: DRUG

Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)

Interventions

ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)

Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Idiopathic or heritable pulmonary arterial hypertension
• New York Heart Association (NYHA) functional class II or III

Exclusion Criteria

• Other causes of pulmonary arterial hypertension (i.e. collagen vascular disease, congenital heart disease, chrono-thromboembolic pulmonary hypertension, pulmonary venous hypertension, left heart failure, hypoxemic lung disease)
• Pulmonary arterial hypertension targeted therapies before study inclusion

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amsterdam UMC, location VUmc

OTHER

Sponsor Role: lead

Responsible Party

A. Vonk Noordegraaf

Clinical Professor, Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Anton Vonk Noordegraaf, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

VU University Medical Center, department of pulmonary diseases

Locations

VU University Medical Center, dept Pulmonary diseases

Amsterdam, , Netherlands

Countries

Netherlands

Other Identifiers

NL41878.029.13

Identifier Type: -

Identifier Source: org_study_id